A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.

被引：1
|
作者：
Fujii, Takeo
Masuda, Hiroko
Cheng, Yee Chung
Yang, Fei
Sahin, Aysegul A.
Naoi, Yasuto
Matsunaga, Yuki
Raghavendra, Akshara Singareeka
Sinha, Arup Kumar
Fernandez, Jose R. Espinosa
James, Anjali
Yamagishi, Keisuke
Matsushima, Tomoko
Tripathy, Debu
Tada, Sachiyo
Jackson, Rubie S.
Noguchi, Shinzaburo
Nakamura, Seigo
Acoba, Jared David
Ueno, Naoto T.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Med Coll Wisconsin, Menomonee Falls, WI USA
[4] Osaka Univ, Dept Breast & Endocrine Surg, Osaka, Japan
[5] Showa Univ, Tokyo, Japan
[6] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[7] Sysmex Corp, Kobe, Hyogo, Japan
[8] Sysmex Corp, Cent Res Labs, Kobe, Hyogo, Japan
[9] Anne Arundel Med Ctr, Rebecca Fortney Breast Ctr, Annapolis, MD USA
[10] Osaka Univ, Dept Breast & Endocrine Surg, Grad Sch Med, Osaka, Japan
[11] Showa Univ, Sch Med, Div Breast Surg Oncol, Dept Surg, Tokyo, Japan
[12] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA
[13] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.542
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
542
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Budget Impact of the Oncotype DX Breast Recurrence Score® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
    Lux, Michael Patrick
    Minartz, Christof
    Mueller-Huesmann, Harald
    Sandor, Marianar Felicia
    Radeck-Knorre, Sabine
    Neubauer, Aljoscha Steffen
    [J]. BREAST CARE, 2024, 19 (01) : 27 - 33
  • [22] Multi-gene assay "Curebest 95GC" for recurrence prediction for ER+/HER2-/n0 breast cancer patients
    Naoi, Yasuto
    Noguchi, Shinzaburo
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [23] Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
    Unal, Caglar
    Ozmen, Tolga
    Ordu, Cetin
    Pilanci, Kezban Nur
    Ilgun, Ahmet Serkan
    Gokmen, Erhan
    Almuradova, Elvina
    Ozdogan, Mustafa
    Guler, Niluefer
    Uras, Cihan
    Kara, Halil
    Demircan, Orhan
    Isik, Selver
    Alco, Gul
    Saip, Pinar
    Aydin, Esra
    Duymaz, Tomris
    Celebi, Filiz
    Yararbas, Kanay
    Soybir, Gursel
    Ozmen, Vahit
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [24] Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database
    Cheng, Ran
    Kong, Xiangyi
    Wang, Xiangyu
    Fang, Yi
    Wang, Jing
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [25] Prognostic value of the 21-gene recurrence score in ER-positive,HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients
    Jiayi Wu
    Weiqi Gao
    Xiaosong Chen
    Chunxiao Fei
    Lin Lin
    Weiguo Chen
    Ou Huang
    Siji Zhu
    Jianrong He
    Yafen Li
    Li Zhu
    Kunwei Shen
    [J]. Frontiers of Medicine, 2021, 15 (04) : 621 - 628
  • [26] Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients
    Wu, Jiayi
    Gao, Weiqi
    Chen, Xiaosong
    Fei, Chunxiao
    Lin, Lin
    Chen, Weiguo
    Huang, Ou
    Zhu, Siji
    He, Jianrong
    Li, Yafen
    Zhu, Li
    Shen, Kunwei
    [J]. FRONTIERS OF MEDICINE, 2021, 15 (04) : 621 - 628
  • [27] Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients
    Jiayi Wu
    Weiqi Gao
    Xiaosong Chen
    Chunxiao Fei
    Lin Lin
    Weiguo Chen
    Ou Huang
    Siji Zhu
    Jianrong He
    Yafen Li
    Li Zhu
    Kunwei Shen
    [J]. Frontiers of Medicine, 2021, 15 : 621 - 628
  • [28] The first report of multicenter validation study on curebest 95GC breast, a multi-gene assay to predict prognosis of node negative and ER positive breast cancer patients.
    Ito, Ken-ichi
    Oba, Takaaki
    Aogi, Kenjiro
    Ohsumi, Shozo
    Takahashi, Mina
    Shiroma, Noriyuki
    Oda, Miyo
    Arihiro, Koji
    Tsukamoto, Fumine
    Shiino, Sho
    Yoshida, Masayuki
    Kishi, Kazuki
    Kinoshita, Takayuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] 21-gene recurrence score assay as a predictor of pathological response in neoadjuvant chemotherapy administration for ER-positive/HER2-negative early-stage breast cancer.
    Morales Murillo, Serafin
    Gasol Cudos, Ariadna
    Rodriguez, Alvaro
    Canosa Morales, Carles
    Mele Olive, Jordi
    Vilardell, Felip
    Sanchez Guzman, Douglas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Estrogen Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancers Have Similar Oncotype DX Recurrence Score Distribution and Prognosis in African American and Caucasian Patients
    Logan, Suzanna J.
    Zhang, Chao
    Liu, Yuan
    Siddiqui, Momin T.
    Cohen, Cynthia
    Li, Xiaoxian
    [J]. LABORATORY INVESTIGATION, 2017, 97 : 56A - 57A
12345